First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
According to the Indian Council of Medical Research (ICMR), there will be an estimated 12 % rise in cancer cases in India in the next five years
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
The investment will accelerate the overall Sarclisa development program
The centre will initially employ 170 engineers, bringing the total number of Boston Scientific’s R&D employees in India to more than 300
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
Subscribe To Our Newsletter & Stay Updated
